Sectors

Healthcare and HealthTech

Healthcare and healthtech financial infrastructure is shaped by reimbursement timelines, regulatory approval sequencing, and a capital structure that must reflect the contingent nature of revenue before market authorization.

Financial Infrastructure Profile

A healthcare company approaching its first institutional raise operates in a financial environment that standard startup financial models cannot accurately represent. The revenue model is contingent on regulatory outcomes that are probabilistic, not certain. The reimbursement model introduces a delay between clinical utilisation and cash receipt that creates a working capital requirement that a simple cash flow model will underestimate. The capital structure must accommodate tranche release conditions tied to clinical or regulatory milestones rather than to commercial performance metrics. Each of these characteristics requires specific financial infrastructure that must exist before a sophisticated life sciences or healthcare investor will engage seriously with the financial model.

HealthTech companies that carry a software revenue model alongside a healthcare product face a different but related challenge: the financial model must separate the software economics from the healthcare product economics because the investors who evaluate these two components apply different benchmarks. The gross margin on a SaaS module for clinical administration is evaluated against software benchmarks. The revenue ramp for a diagnostic device is evaluated against medtech benchmarks. A blended model that does not make this separation obscures both sets of economics and makes it difficult for any investor to apply a coherent analytical framework.

Sector-Specific Financial Challenges

  • Reimbursement timeline modeling: the delay between clinical utilisation and cash receipt under payer reimbursement structures must be modeled explicitly in the cash flow forecast, with the working capital requirement calculated at weekly resolution during the ramp period
  • Regulatory approval milestone modeling: the financial model must incorporate the primary regulatory approval milestone as the trigger for commercial revenue, with the cash consumption and capital requirement through the approval process calculated across at minimum two duration scenarios
  • Capital structure for milestone-based funding: the cap table and the use of proceeds must reflect the tranche structure of the raise, with each tranche's release condition defined and the financial model structured to show that the company reaches the next milestone before the previous tranche is exhausted
  • Clinical trial cost modeling: the cost of the clinical validation program must be modeled as a discrete cost center with the spend profile mapped to the trial protocol timeline, not aggregated into a general research and development line
  • Intellectual property valuation methodology: for companies with a product that depends on patent protection, the valuation analysis must address the IP position explicitly and select a methodology that is defensible in the context of the patent estate and the regulatory status
  • Insurance coding and reimbursement rate modeling: the revenue model must document the specific reimbursement codes the product will be billed under, the applicable rates for each payer category, and the assumed payer mix at each stage of commercial rollout
  • Post-approval commercial ramp modeling: the revenue forecast must model the adoption curve from initial approval through full commercial deployment with explicit assumptions about sales force deployment, payer contracting timelines, and clinician adoption rates

Relevant Service Layers

Relevant Models

Selected Outcome

Raise Layer · Healthcare and HealthTech · Seed Stage

The company was preparing a Series A raise to fund the MHRA approval process for a medical device and the subsequent commercial launch. The financial model had a single revenue line beginning eighteen months from the raise date with no assumption documentation for the approval timeline, no reimbursement delay in the cash flow model, and no scenario analysis for an extended approval period. Oakworth rebuilt the model with the MHRA approval milestone as a discrete trigger in the revenue model with two duration scenarios, modeled the reimbursement delay in the cash flow as a function of the payer mix and the average days-to-payment for each payer category, and structured the raise as a two-tranche arrangement with the first tranche funding the approval process and the second tranche releasing on approval confirmation. The Series A process received three term sheets. The selected investor cited the milestone-based capital structure as evidence that the management team understood the approval risk and had structured the financing to manage it.